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Summary
AML1/ETO is the chimeric protein resulting from the t(8;21) in acute myeloid leukemia. The Nervy homology 2 (NHR2) domain
in ETO mediates oligomerization and AML1/ETO’s interactions with ETO, MTGR1, and MTG16, and with the corepressor mol-
ecules mSin3A and HDAC1 and HDAC3. We solved the NHR2 domain structure and found it to be an a-helical tetramer. We
show that oligomerization contributes to AML1/ETO’s inhibition of granulocyte differentiation, is essential for its ability to
enhance the clonogenic potential of primary mouse bone marrow cells, and affects AML1/ETO’s activity on several endog-
enous genes. Oligomerization is also required for AML1/ETO’s interactions with ETO, MTGR1, and MTG16, but not with other
corepressor molecules.Introduction
AML1/ETO is the fusion protein resulting from the t(8;21) found
in acute myeloid leukemia (AML) of the M2 subtype (Miyoshi
et al., 1993). AML1/ETO contains the N-terminal 177 amino
acids of RUNX1 fused in frame with most (575 aa) of ETO.
RUNX1 (AML1) is the sequence-specific DNA binding subunit
of a core binding factor that is required at multiple stages of he-
matopoiesis (Growney et al., 2005; Ichikawa et al., 2004; Okuda
et al., 1996; Wang et al., 1996). The Runt domain of RUNX1,
which is retained in AML1/ETO, mediates DNA binding as well
as heterodimerization with the core binding factor b (CBFb)
subunit. ETO (eight twenty-one) was originally identified as the
RUNX1 fusion partner in t(8;21), and many of its biochemical
properties have been characterized in light of its role in leukemo-
genesis. The function of ETO itself is less well understood, al-
though itsDrosophila homolog, Nervy, was recently shown to in-
teract directly with the transcription factor daughterless, and to
repress the activity of enhancers normally activated by theCANCER CELL 9, 249–260, APRIL 2006 ª2006 ELSEVIER INC. DOI 10.10achaete-scute complex in the sensory organ precursor cell
(Wildonger and Mann, 2005). Homozygous disruption of ETO
in mice results in a gastrointestinal defect, but no hematopoietic
deficiencies were reported (Calabi et al., 2001). A second ETO
family member, MTG16, was purified as part of a complex of
transcription factors by virtue of their association with the hema-
topoietic-specific SCL protein (Schuh et al., 2005). MTGR1, the
third member of the mammalian ETO family, is required for the
maintenance of secretory epithelial cells in the small intestine
(Amann et al., 2005). MTG16 is also translocated to RUNX1 in
human leukemia (Gamou et al., 1998), potentially underscoring
the importance of sequences that are conserved between the
ETO proteins for their oncogenic properties.
ETO shares four regions of homology with Nervy (NHR1-4), all
four of which are retained in AML1/ETO (Davis et al., 2003; Hug
and Lazar, 2004). NHR1 is homologous to several TATA binding
protein-associated factors (TAFs) and interacts with E proteins
(Zhang et al., 2004). NHR2 is often referred to as the hydropho-
bic heptad repeat (HHR) because its amino acid sequence isS I G N I F I C A N C E
Chromosomal rearrangements often result in the production of chimeric proteins with altered function. In a number of cases, aberrant
oligomerization of kinases or transcription factors through the addition of oligomerization domains contributes substantially to the on-
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A R T I C L ETable 1. Statistics of data collection and refinement
Data statisticsa
Wavelength (A˚) 0.97946 inflection 0.97915 peak 0.96422 remote
Resolution range (A˚) 50.0–2.0 50.0–2.0 50.0–2.0
Total number of reflections 143610 233291 106989
Unique reflections 10199 10096 9499
*Rmerge 0.026 (0.195) 0.044 (0.196) 0.037 (0.233)
**Anomalous Rmerge 0.020 (0.172) 0.021 (0.175) 0.020 (0.211)
*Completeness (%) 98.6 (93.8) 99.7 (100.0) 91.9 (92.8)
**Anomalous completeness (%) 96.4 (89.8) 99.7 (99.8) 84.7 (80.5)
**Anomalous average redundancy 2.4 (2.0) 3.6 (3.2) 1.8 (1.8)
Average I/s(I) 27.0 (6.4) 24.9 (5.5) 20.1 (4.5)
Refinement statisticsb
Resolution (A˚) 40.0–2.0
Unique reflections 9346 (645)
R (%) 21.6 (22.6)
Rfree (%) 27.0 (33.7)
No. non-H protein atoms 1099
No. water molecules 59
R.m.s.d. bond lengths (A˚) 0.021
R.m.s.d. bond angles (º) 2.794
R.m.s.d. torsion angles (º) 6.186
Average B factor (A˚2) 32.0
Ramachandran plot
Residues in most favored region (%) 97.4
Residues in additional allowed regions (%) 2.6
aData for the highest resolution shells are in parentheses: peak (2.07–2.00 A˚), inflection, and remote (2.06–2.00 A˚). *Friedel mates merged. **Friedel mates
separated.
bData for the highest resolution shell (2.05–2.00 A˚) are given in parentheses.indicative of an amphipathic helical structure (Lutterbach et al.,
1998a). NHR2 contributes many of the most well-studied bio-
chemical properties of ETO, including oligomerization and pro-
tein-protein interactions (Amann et al., 2001; Hildebrand et al.,
2001; Lutterbach et al., 1998a; McGhee et al., 2003; Zhang
et al., 2001). NHR3 is a predominantly a-helical domain (Yang
et al., 2004) that interacts with the regulatory subunit of type II
cyclic AMP-dependent protein kinase (PKA RIIa) (Fukuyama
et al., 2001); however, its contribution to AML1/ETO function
may be cooperative with adjacent domains (Hildebrand et al.,
2001). NHR4, also known as the myeloid-Nervy-DEAF-1 (MYND)
domain, has two putative, non-DNA binding zinc fingers. Like
NHR2, NHR4 mediates protein-protein interactions thought to
be important for leukemogenesis (Gelmetti et al., 1998; Lutter-
bach et al., 1998a; Wang et al., 1998).
The NHR2 domain mediates interactions with ETO family
members, oligomerization of AML1/ETO, and interactions with
mSin3A, Gfi-1, BCL6, and HDAC1 and HDAC3 (Hiebert et al.,
2001; Hug and Lazar, 2004). The generation of oligomeric tran-
scription factors by translocation partner sequences is emerg-
ing as a common transforming mechanism in many hematolog-
ical malignancies (So and Cleary, 2004). It has been proposed
that oligomerization generates a surface required for high-
affinity corepressor interactions, and in the case of AML1/ETO,
oligomerization was shown to augment SMRT interaction in vitro
(Zhang et al., 2001). Here, we present the crystal structure of the
isolated NHR2 domain. NHR2 forms a four-helix bundle tetra-
meric structure stabilized by an extensive hydrophobic interface
contributed by the four amphipathic a helices and specific inter-
subunit electrostatic interactions. We introduced amino acid
substitutions into NHR2 with the goal of disrupting oligomeriza-
tion while maintaining solubility andminimally compromising the250helical secondary structure, and confirm that oligomerization is
critical for AML1/ETO function in vivo.
Results
Structure determination
We crystallized the SeMet substituted NHR2 domain (residues
480–551, AML1/ETO numbering), collected diffraction data
from a single crystal at three wavelengths (0.97915 A˚ [peak],
0.97946 A˚ [inflection], and 0.96422 A˚ [remote]), and solved the
structure at 2.0 A˚ resolution by multiple wavelength anomalous
dispersion (MAD). We traced residues 490–548 in both protein
chains but observed no continuous electron density that could
be used for model building for residues 480–489 and 549–551.
Details of data collection and structure determination are sum-
marized in Table 1. The coordinates and structure factors are
deposited in the Protein Data Bank with accession code 1WQ6.
The asymmetric unit contains two molecules (Figure 1A) re-
lated by an ‘‘approximate’’ 2-fold noncrystallographic symmetry
(backbone r.m.s.d.: 0.97 A˚). Each polypeptide chain consists of
one long curved a helix (Asp495–Ala547) with a kink at Ile512.
The homotetrameric model is established by rotating the asym-
metric unit around the 2-fold axis of the P21212 space group
(Figure 1A). The two antiparallel molecules in the asymmetric
unit are aligned at 173.6º in a head-to-tail fashion and lie on
top of the other antiparallel pair (Figure 1B: C3 and C4) at
a 21º angle to form a left-handed supercoil. Indeed, the NHR2
primary sequence displays the 7-residue repeat characteristic
of left-handed coiled coils (Antonin et al., 2002; Harbury et al.,
1993) (Figure 2A). The monomer is amphipathic and interacts
with the other threemonomers throughhydrophobic interactions
that bury a total accessible surface area (ASA) of 10,645 A˚2CANCER CELL APRIL 2006
A R T I C L EFigure 1. Structure of the NHR2 domain
A: Unit cell packing: there are four half tetramers
per unit cell. Only two halves are shown for clar-
ity. Lowercase a, b, and c denote the unit cell
axes.
B: Ribbon representation of the tetramer in two
different orientations. The four chains in the tetra-
mer are labeled C1, C2, C3, and C4. The asym-
metric unit can be chosen so that it contains
C1 and C2 (red). C3 and C4 (green) are related
to C1 and C2 by crystallographic symmetry. The
kink at Ile512 is indicated. N0 and C0 denote the N
and C termini.
C: Surface views of a single molecule (C1). Elec-
trostatic distribution on the two sides of the am-
phipathic helix is shown on the left, with positively
charged (blue), negatively charged (red), and
uncharged (ivory) atoms indicated. Right: distri-
bution of solvent-accessible surface area on
the two sides of the amphipathic helix. Residues
with >50% of their solvent-accessible surface
area buried in the tetramer are shown in green.
N0 denotes the N terminus.(average of 2661 A˚2 per monomer). The large contact area is
consistent with oligomerization rather than crystal contacts.
The tetrameric structure was predicted by PITA (protein interac-
tions and assemblies) (Ponstingl et al., 2000) and confirmed in
solution by analytical ultracentrifugation (Table 2).
The tetramer forms an interaction motif through
hydrophobic heptad repeats and ionic/polar interactions
The NHR2 tetramer contains an N-terminal tetrameric region
with ten symmetrical interacting layers (25 to 21 and 1 to 5)
and two symmetrical C-terminal dimeric regions with five inter-
acting layers (e0–a0 and a–e) (Figure 2A). This unusual interaction
pattern occurs as a result of the indented alignment of the anti-
parallel molecules and the relatively small intersection angle
(21º) between the two dimers. To the best of our knowledge,
such an interaction motif has not been reported previously.
Most of the layers consist of hydrophobic residues at the ‘‘a’’
and ‘‘d’’ positions of the heptad helical wheel (Figures 2A and
3B). The two molecules in the asymmetric unit (C1 and C2, or
C3 and C4) display some asymmetry not only in conformation
but also in contact surface (Figures 1B and 2D). All the ‘‘a’’
and ‘‘d’’ residues in the tetrameric region of both molecules
are more than 90%buried (Figure 2D), and ‘‘a’’ and ‘‘d’’ residues
in the dimeric region are more than 65% buried, except for
Ala547, which is at the very end of the helix. This is similar to
what is observed for the dimeric leucine zipper domain of
GCN4 (Harbury et al., 1993). The ‘‘e’’ and ‘‘g’’ residues in the tet-
rameric region are greater than 60% buried (Figure 2D), consis-
tent with what has been reported for a tetrameric mutant of
GCN4: p-LI (Harbury et al., 1993). The hydrophobic core is
packed between the four molecules in a sandwich-like fashion
(Figure 2C).
A number of polar and charged residues make important sta-
bilizing interactions that are not typically seen in leucine zippers.
For example, the Thr519 side chains are buried in layers +2 and
22, and Gln530 is packed in layers +5 and 25 (Figure 2A).CANCER CELL APRIL 2006The hydroxyl group of Thr519 forms an intramolecular hydrogen
bond with the carbonyl group of Met515 (Thr519 Og 2 Met515
CO = 2.8 A˚) (data not shown). This type of hydrogen bonding
between Thr i and X i-4 has also been observed in the endoso-
mal SNARE complex (Antonin et al., 2002; Fasshauer et al.,
1998). In layers +5 and 25, Gln530 of C1 forms a specific
intermolecular hydrogen bond with Trp502 of C2 (Gln530 O3 2
Trp502 N31 = 2.96 A˚), while asymmetrically, Gln530 of C4 in
the same layer displays an intermolecular hydrogen bond with
Leu526 of C1 (Gln530 N32 2 Leu526 O = 3.11 A˚) (Figure 2E).
Two symmetrical groups of intermolecular salt bridge interac-
tions are observed in the tetrameric complex (Figure 2F). One
consists of intermolecular interactions between Arg520 and
Asp506 that form solvent-exposed salt bridges (Figure 2F).
This type of surface ionic interaction was shown to be important
for stability in theGCN4 dimer (Spek et al., 1998). The other sym-
metrical group occurs at layers a and a0 and involves residues at
the ‘‘a’’ and ‘‘d’’ positions of the heptad helical wheel. In leucine
zipper oligomers, there are buried hydrophobic residues at
these locations that contribute to oligomerization, but the
NHR2 tetramer instead contains charged residues that form
buried salt bridges with good geometry. For example, Asp533
of C2 forms salt bridges with Arg534 of C3 (Figure 2F). Both
Asp533 and Arg534 are almost completely buried (Figure 2D),
and the highly favorable electrostatic interaction energy offsets
the desolvation penalty for burying the charges.
Oligomerization contributes to AML1/ETO’s activity
We assessed the importance of oligomerization for AML1/ETO
function by introducing amino acid substitutions into NHR2
that disrupt tetramer formation. We sought to achieve three
goals when designing the mutations: (1) to disrupt the oligomer-
ization interface, (2) to confer favorable solubility properties to
the mutant domain, and (3) to preserve the a-helical secondary
structure as much as possible. The Leu residues at the interface
contribute substantially to the stability of the tetramer, and251
A R T I C L EFigure 2. Analysis of the NHR2 structure
A: Primary sequence alignment of the NHR2 domain based on the actual topology. Residues occupying the ‘‘a’’ and ‘‘d’’ positions of the canonical heptad
helical wheel are colored red. The ‘‘a’’ and ‘‘d’’ positions in the tetrameric layers are labeled with numbers (25 to21 and 1 to 5) and in the dimeric layers with
letters (e0–a0 and a–e). Layers related by opposite signs or primes are strictly symmetrical in the structure.
B: Selected cross-sections of hydrophobic layers. The four molecules are labeled with different colors for clarity.
C: Packing of the hydrophobic core in the tetramer. Residues with >90% of their solvent-accessible surface buried in the tetramer are shown in green.
D: Solvent-accessible surface area for residues that are >90% buried in C1 or C2. The position in the helical wheel is also indicated. Residues with values <90%
are indicated with an asterisk.
E: The intermolecular hydrogen bonds at layer +5 involving Gln530, Leu526, and Trp502.
F: Detailed views of two salt-bridged layers. Hydrogen-bonded salt bridges are shown as black dashed lines, and non-hydrogen-bonded salt bridges are
shown as green dashed lines (defined as in Kumar and Nussinov, 1999).therefore we targeted them for mutagenesis. We tried several
different substitutions (see Table S1 in the Supplemental Data
available with this article online), only two of which significantly
disrupted tetramer formation, and which are reported here.
The m7 mutant contained Arg and Glu substitutions for the
seven Leu residues, with the charged residues placed appropri-
ately for favorable intrahelical electrostatic interactions (Fig-
ure 3B). The placement of charge on the interface was designed
to disrupt oligomerization and provide favorable solubility prop-
erties to the monomeric domain. In addition, both Arg and Glu
have a high a-helical propensity, so it was hoped that the252monomeric domain would retain some of its a-helical character.
The m4 mutant had four Leu residues replaced with Lys, Glu, or
Gln (Figure 3B). The three Leu residues at the reported interface
for mSin3A (Amann et al., 2001) were not altered in m4. Finally,
we substituted two solvent exposed residues (m2, Figure 3B)
that were required for mSin3A binding to the isolated NHR2 do-
main (Amann et al., 2001).
We characterized the solution oligomerization state and sec-
ondary structure of the wild-type and mutant NHR2 domains by
sedimentation velocity and circular dichroism (CD) spectros-
copy, respectively. Figure 3C shows that the continuousCANCER CELL APRIL 2006
A R T I C L Esedimentation coefficient distribution for NHR2 contains amajor
peak near s = 2.7 S, corresponding to 91% of the material. The
molecular mass of this predominant species is 36.1 kDa (Table
2) which corresponds closely to the predicted tetramer mass
of 35.8 kDa. Thus, the NHR2 domain is clearly a tetramer in so-
lution. Hydrodynamic modeling using the crystal structure pre-
dicts a sedimentation coefficient of 2.87 S, which agrees well
with the experimental value of 2.68 S.
The sedimentation coefficient of m7 was w1.1 S and the
mass 7.6 kDa, indicating that m7 is a soluble monomer (Fig-
ure 3C and Table 2). CD spectroscopy indicates that the per-
centage of residues with helical secondary structure was re-
duced from 60% in NHR2 to 17% in the m7 mutant (Figure 3D).
The m4 mutant was tetrameric at 20ºC by analytical ultracentri-
fugation (Table 2), but CD spectroscopy revealed that it was only
41% helical, suggesting that the m4 tetramer is significantly de-
stabilized. We characterized the stability of m4more extensively
by thermal denaturation and renaturation experiments moni-
tored by CD spectroscopy. The NHR2 domain unfolds with a
sharp transition at a melting temperature >90ºC (Figure S1), in-
dicative of the extremely high stability of the tetramer. In con-
trast, m4 unfolding occurs with a broad transition and amidpoint
around 50ºC; therefore, the m4 tetrameric structure should be
destabilized at physiological temperatures. The m2 domain is
tetrameric and has a similar sedimentation coefficient (Table 2)
and CD spectrum (Figure 3D), and therefore similar structure
as the NHR2 domain.
We deleted the NHR2 (Figure 3A) and introduced the m7,
m4, and m2 mutations into full-length AML1/ETO and assessed
their effect on oligomerization by size exclusion chromatogra-
phy (SEC) (Figure 3E). As shown by others (Minucci et al.,
2000; Zhang et al., 2001), full-length AML1/ETO (84 kDa) mi-
grates with an apparent molecular mass greater than 400 kDa.
Deletion of the NHR2 domain (Zhang et al., 2001), the m7 muta-
tion, and the m4 mutation shifted the migration of AML1/ETO to
that of lower-molecular weight species (Figure 3E). Consistent
with the sedimentation velocity and CD measurements, the
m4 version of AML1-ETO shows an elution volume intermediate
between m7 and AML1-ETO. Them2mutation did not affect the
SEC elution profile (data not shown).
Table 2. Analysis of NHR2 oligomerization by sedimentation velocitya
Protein Mass (kDa) s (svedbergs) % Contributionb r.m.s.c
NHR2d 36.1 2.68 91 0.0069
m7e 7.6 1.09 92 0.0117
m4d 33.3 2.85 84 0.0109
m2f 34.2 2.71 91 0.0053
aSedimentation profiles obtained at two to three loading concentrations
were globally analyzed with SEPHAT using a hybrid discrete-continuous dis-
tribution model to obtain the mass and sedimentation coefficient of the
majority species for each protein.
bThe weight percent contribution of the majority species was obtained by
integration of a continuous sedimentation coefficient distribution function
from w1.9 to w3.5 S with SEDFIT. Large aggregates with s > 100 S were ob-
served in several samples and were not included in the analysis.
cRoot mean square deviation of the global fit in units of OD (absorbance) or
fringes (interference).
dData obtained at 0.6, 0.3, and 0.1 mg/ml using absorbance at 280 nm.
eData obtained at 0.2, 0.09, and 0.05 mg/ml using absorbance at 230 nm.
Approximately 30%–45% of the material sedimented with s > 100 S.
fData obtained at 0.15, 0.09, and 0.05 mg/ml using absorbance at 230 nm.
Approximately 25% of the material sedimented with s > 100 S.CANCER CELL APRIL 2006We used retroviruses to introduce AML1/ETO and its mutated
derivatives into lineage-depleted (CD52, B2202, Mac-12,
Gr-12, Ter1192) mouse bone marrow cells (Lin2 BM) in order
to assess the importance of oligomerization for AML1/ETO func-
tion. The retroviruses also expressed the green fluorescent pro-
tein (GFP) from an internal ribosome entry site, allowing us to
monitor successfully transduced cells. We cultured the trans-
duced cells for 2 days in the presence of IL-3, IL-6, and SCF,
and for 7 additional days with the same cytokines plus G-CSF
to induce granulocyte differentiation, and analyzed GFP+ cells
for cell surface Gr-1 and Mac-1 expression (Figure 4A). Approx-
imately 20% of Lin2 BM cells expressing GFP alone were Gr-1+
Mac-1+, whereas only 3% of cells expressing AML1/ETO differ-
entiated into Gr-1+Mac-1+ cells. As shown by Hug et al. (2002),
deletion of the NHR2 domain partially impaired AML1/ETO’s
repression of granulocyte differentiation, resulting in a 3-fold in-
crease in the percentage of Gr-1+Mac-1+ cells. Them7mutation
increased the percentage of Gr-1+Mac-1+ cells to the same ex-
tent as the NHR2 deletion. The m4 mutation impaired AML1/
ETO’s activity, but significantly less so than the NHR2 deletion.
Them2mutation had no effect on AML1/ETO’s ability to repress
granulocyte differentiation.
An AML1/ETO protein truncated at aa 542, C-terminal to the
NHR2 domain (NHR2x; Figure 3A) partially inhibits the differen-
tiation of Gr-1+Mac-1+ cells, and the m7 mutation in the context
of this truncated NHR2x protein (NHR2x m7) completely abro-
gates AML1/ETO’s activity (Figure 4A). All of the mutated pro-
teins accumulated to similar steady-state levels in retrovirus-
infected NIH 3T3 cells despite the fact that the m4 and m7
mutations partially destabilized NHR2’s helical structure
(Figure 4B).
Disruption of oligomerization abrogates AML1-ETO’s
ability to promote self-renewal
We assessed the importance of tetramer formation for AML1/
ETO’s ability to confer increased self-renewal capacity on he-
matopoietic progenitors in vitro (Higuchi et al., 2002; Hug
et al., 2002; Mulloy et al., 2002). Lin2 BM cells were infected
with retroviruses expressing AML1/ETO and its mutated deriva-
tives and cultured in IL-3, IL-6, and SCF. Cells expressing AML1/
ETO could be propagated for at least 3 weeks in culture and
yielded primarily immature myeloid lineage cells (Figures 4C
and 4D) and a smaller percentage of differentiated macro-
phages (data not shown). In contrast to the results of Hug
et al. (2002), we found that deletion of NHR2 completely abol-
ished AML1/ETO’s ability to sustain clonogenic activity in vitro,
as did the m7 and m4 mutations (Figure 4C). Mutation of the
mSin3A binding site in NHR2 (m2), however, had no effect on
AML1/ETO’s ability to confer enhanced clonogenic potential
(Figure 4C). Truncation of AML1/ETO at the C terminus of
NHR2 (NHR2x) eliminated AML1/ETO’s clonogenic activity, de-
spite the observation that a similar construct retaining 9 addi-
tional amino acids and a terminal four-residue insertion was
shown to augment AML1/ETO’s leukemogenic activity in mice
(Yan et al., 2004).
Disruption of AML1/ETO oligomerization alters
endogenous gene expression
We transduced Lin2 BM cells with retroviruses expressing GFP
alone, AML1/ETO, or m7 and assessed the expression levels of
candidate target genes 2 days posttransduction by real-time253
A R T I C L EFigure 3. Mutations in the NHR2 domain and their effect on tetramer formation
A: Schematic diagram of AML1/ETO. The Runx1 (AML1) portion is green, and ETO sequences are blue. Truncations and internal deletions used in the analyses
are shown below. Parentheses in DNHR2 delineate the extent of the deletion. RD, Runt domain.
B: Sequence of the NHR2 domain (Leu in bold, the two amino acids required for mSin3A binding [Amann et al., 2001] in green) and the mutations designed to
disrupt tetramer formation (m7 and m4) and mSin3A binding (m2). Diagramed below are the m7 and m4 mutations in NHR2 in a helical wheel representation.
Substituted amino acids are red.
C: Sedimentation velocity analysis of NHR2 and the m7 mutant. Absorbance data at 280 nm (NHR2) and 230 nm (m7) were collected at a rotor speed of 50,000
rpm at 20ºC in aluminum-filled Epon double sector cells at a scan interval of approximately 260 s.
D: Circular dichroism spectroscopy of NHR2 domains (recorded at 25ºC). The reduction in ellipticity at 222 nm for m7 and m4 is indicative of a loss of helical
secondary structure.
E: Size exclusion chromatography (SEC) demonstrating that deletion of the NHR2 domain and the m7 and m4 mutations reduces the apparent molecular
weight of full-length AML1/ETO. Proteins were produced by in vitro transcription/translation and fractionated by SEC on a Superdex 200 column, and fractions
were analyzed by Western blot using an anti-Runt domain antibody. Fraction numbers are indicated above lanes, and molecular weight markers are on the
bottom. (2), reticulocyte lysate incubated with the pcDNA vector; L, load.PCR (Figures 5A–5D). Genes that were analyzed were either
previously implicated as Runx1 or AML1/ETO targets (Elagib
et al., 2003; Otto et al., 2003; Peterson and Zhang, 2004) or iden-
tified based on hybridization to pathway-specific microarrays
(data not shown). Other labs have reported that AML1/ETO ex-
pression activates some genes and represses others (Shimada
et al., 2000, 2002), and we likewise observed several different
patterns resulting from AML1/ETO and m7 expression. Some
genes previously shown to be activated by Runx1, including
Art1, Csf1r (MCSFR), Ela2 (neutrophil elastase [NE]), and Sfpi1
(PU.1) (Otto et al., 2003; Peterson and Zhang, 2004) were re-
pressed in Lin2 BM cells transduced with AML1/ETO, and the
m7 mutation restored their expression to the levels observed
in cells expressing GFP alone (Figure 5A). The cell cycle gene
E2f2 and the Jak2 kinase gene also fell into this category. A sec-
ond pattern seen with Itga2b (CD41), Mpo, and Ccnd3 (CycD3)
was that AML1/ETOhad no significant effect, whilem7 activated
their expression (Figure 5B). These three genes were previously
shown to be direct (activated) targets of Runx1. A third pattern254seen with Fos (c-fos), the Cd53 tetraspanin gene, and Cdkn1a
(p21) was activation by AML1/ETO, with blunting of that activa-
tion by the m7 mutation (Figure 5C). Finally, expression of nei-
ther the putative AML1-ETO target gene Bcl2, nor Bmi1 was
significantly altered in the presence of either AML1/ETO or m7
(Figure 5D).
AML1/ETO’s interaction with members of the ETO family
of proteins, but not with other corepressors, requires
oligomerization
AML1/ETO has been shown to interact directly or indirectly with
a number of other proteins, including HDAC1, HDAC2, and
HDAC3, N-CoR, SMRT, mSin3A, Gfi-1, BCL6, PLZF, PKA
RIIa, HEB, and other ETO family members (Hiebert et al.,
2001; Hug and Lazar, 2004). We examined whether oligomeriza-
tion through the NHR2 domain affects the direct or indirect as-
sociation of AML1/ETO-interacting proteins in vivo. FLAG- or
HA-tagged versions of interacting proteins were coexpressed
with either HA-tagged or untagged versions of AML1/ETO orCANCER CELL APRIL 2006
A R T I C L EFigure 4. AML1/ETO function is impaired by mutations that disrupt tetramer formation, but not by mutations in the mSin3A binding site
A: Representative flow of Lin2 BM cells infected with MigR1 retroviruses expressing AML1/ETO and mutated derivatives, following 7 days of culture in the pres-
ence of IL-3, IL-6, SCF, and G-CSF. Cells in the R1 gate were analyzed for GFP expression, and GFP-positive cells (R2) were examined for Mac-1 and Gr-1 ex-
pression. The experiments were performed at least twice with triplicate samples. The average percentages of Gr-1+Mac-1+ cells (6 standard deviation) in the
illustrated experiments were as follows. Experiment #1: MigR1 (GFP alone), 19.3% (1.1); AML1/ETO, 3.6% (0.2); DNHR2, 10.8% (1.0); m7, 8.9% (1.0); m4, 7.5% (0.3).
The difference between m7 and m4 versus AML1/ETO was significant (p % 0.01). m7 was not significantly different from DNHR2 or m4. m4 was significantly
different from DNHR2 (p% 0.05). Experiment #2: MigR1, 15.6% (2.1); AML1/ETO, 1.5% (0.1); m2, 1.8% (0.1). m2 and AML1/ETO were not significantly different.
Experiment #3: MigR1, 22.4% (5.0); AML1/ETO, 3.1% (0.7); NHR2x, 9.2% (1.1); NHR2x m7, 19.1% (1.5). The difference between MigR1 and NHR2x m7 was not sig-
nificant.
B: Western blot probed with an antibody to the Runt domain, demonstrating expression of AML1/ETO and its mutated derivatives in MigR1-transduced NIH3T3
cells.
C: Serial replating of bone marrow cells. Graphs represent the average number of colonies from each round of replating in the presence of IL-3, IL-6, and SCF.
Plating number 1 represents colony numbers per 103 cells plated, and plating numbers 2 and 3 are from 104 plated cells. Numbers are averaged from two
experiments, each containing triplicate samples. The average numbers of cells (6 SD) at week three of replating are as follows: AML1/ETO, 117 (9.5); m2,
141 (26). The other cultures had no cells at 3 weeks.
D: Cytospin preparation of cells expressing AML1/ETO from the third replating. The majority of cells (w85%) were immature myelocytes or monocytes, and the
remainder were primarily macrophages (data not shown). Only a few mature granulocytes were visible (data not shown).CANCER CELL APRIL 2006 255
A R T I C L EFigure 5. Oligomerization influences AML1/ETO’s regulation of gene expression, but not its association with interacting proteins, with the exception of ETO,
MTG16, and MTGR1
A–D: Real time PCR of putative Runx1 or AML1/ETO target genes in Lin2 BM cells to assess the role of oligomerization in gene expression. Gene expression data
are presented as the fold change between control EGFP-transduced cells (normalized to a value of 1, dashed line) and AML1/ETO or m7-transduced cells and
represent averages from three independent experiments. Error bars indicate 95% confidence intervals. A: Genes whose expression is repressed in the pres-
ence of AML1/ETO and m7 restores expression to that of EGFP alone. B: Genes activated by m7 but not AML1/ETO. C: Genes activated by AML1/ETO and
less so by m7. D: Examples of genes whose expression is not affected by either AML1/ETO or m7. The 2-fold reduction in EGFP expression, which was equivalent
for AML1/ETO and m7, was most likely due to its translation from bicistronic (AML1/ETO and m7) versus monocistronic (EGFP alone) mRNAs.
E: Cos7 cells were cotransfected with HA-tagged (AML1/ETO [A/E] and m7) or nontagged (DNHR2, m4, NHR3x, NHR2x, NHR2x m7, NHR2x m2) AML1/ETO pro-
teins and FLAG-tagged HDAC1, HDAC2, HDAC3, N-CoR, SMRT, PKA RIIa, or HEB. For experiments involving ETO homologs, cells were transfected with HA-
tagged ETO, MTG16, and MTGR1 and untagged AML1/ETO. Top panels: cell lysates immunoprecipitated (IP) with anti-FLAG or anti-HA antibody and blotted
with antibody to the Runt domain (RD) in AML1/ETO. The interaction between mSin3A and transfected AML1/ETO proteins was analyzed by immunoprecipi-
tating endogenous mSin3A and blotting with the anti-RD antibody. Middle panels: 1% of input lysate, blotted with anti-RD to detect AML1/ETO proteins. Bot-
tom panels: membranes from the top panel were reprobed with anti-FLAG, anti-HA, or anti-mSin3A antibodies. The percentages of input AML1/ETO and m7
proteins in the immunoprecipitates were determined by titration analyses and were as follows: HDAC1, 1.5 and 1.4 (AML1/ETO and m7, respectively); HDAC2,
0.7 and 0.7; HDAC3, 1.3 and 1.3; mSin3A, 0.6 and 0.3; N-CoR, 0.8 and 0.7; SMRT, 0.9 and 0.9; PKA RIIa, 1 and 1; PLZF, 0.8 and 0.7, HEB, 1 and 0.4. ETO homolog
immunoprecipitates were not quantified.its mutated derivatives in Cos7 cells, and their interactions were
monitored by coimmunoprecipitation (Figure 5E). The interac-
tion of AML1/ETO with endogenous mSin3A was also exam-
ined. We found that deletion of the NHR2 domain weakened
full-length AML1/ETO’s interactions with mSin3A, to some ex-
tent with HDAC2, and dramatically affected interactions with
all of the ETO family proteins (ETO, MTG16, and MTGR1). How-
ever, when AML1/ETO oligomerization was specifically dis-
rupted by the m7 mutation, only the interactions with ETO,
MTG16, and MTGR1 were markedly affected. The m7 mutation
in the context of an AML1/ETO protein truncated at the256C terminus of the NHR2 domain (NHR2X versus NHR2Xm7)
did disrupt binding to mSin3A and may have weakened the in-
teraction with N-CoR, but it did not noticeably or consistently af-
fect the efficiency of coimmunoprecipitation with the HDACs,
HEB, SMRT, or PLZF. m4 weakened full-length AML1/ETO’s in-
teraction with mSin3A and almost completely abrogated its abil-
ity to coimmunoprecipitate with SMRT, but sincem4 did not dis-
rupt oligomerization to the same extent as m7, the weakened
binding to mSin3A and SMRT was not specifically caused by
the loss of oligomerization. In summary, although AML1/ETO’s
in vivo activity is dependent on oligomerization, its binding toCANCER CELL APRIL 2006
A R T I C L Ethe ectopically expressed corepressor proteins, with the excep-
tion of the ETO family of proteins, was not appreciably affected
by mutations that specifically impair oligomerization.
Discussion
Oligomerization is important for the oncogenic potential of
a number of leukemia-associated chimeric proteins. This phe-
nomenon was originally documented for the BCR/ABL kinase
(McWhirter et al., 1993), and in transcription factors was first ob-
served for fusion proteins involving the retinoic acid receptor
a (RARa) (Lin and Evans, 2000; Minucci et al., 2000). Since these
initial observations, an in vivo role for oligomerization has been
documented for chimeric transcription factors containing
RUNX1 (AML1/ETO, AML1/MTG16, TEL/AML1), CBFb (CBFb/
SMMHC), RARa (NPM/RARa, PML/RARa, PLZF/RARa, NuMA/
RARa, Stat5b/RARa), and MLL (MLL/GAS7, MLL/AF1p, MLL/
GEPHRIN), which together account for a high percentage of
leukemia cases (Eguchi et al., 2004; So and Cleary, 2004). The
paradigm for the effects of aberrant oligomerization on tran-
scription factor function is the fusion of RARa to PML and PLZF
in acute promyelocytic leukemia, which affects RARa’s in vivo
function and its binding to the corepressors N-CoR and SMRT
(Melnick and Licht, 1999).
The NHR2 domain of ETO is also an oligomerization domain,
and it is important for AML1/ETO’s activity. Our structural results
show that NHR2 forms a homotetrameric a-helical bundle with
a left-handed supercoil resembling the structure found in the
heterotrimeric SNARE complexes (Sutton et al., 1998). We
used the NHR2 structure to design mutations that disrupted
oligomerization but conferred favorable solubility properties to
the domain and preserved a significant proportion of its second-
ary structure. Unlike a deletion, the mutations we employed do
not create artificial restrictions on the relative positioning of
other domains and may retain some of the protein-protein inter-
actions mediated by the NHR2 domain. Mutations designed to
disrupt oligomerization were introduced into full-length AML1/
ETO to determine which biological and biochemical properties
previously ascribed to oligomerization through deletion studies
can actually be attributed to oligomerization per se. Our results
confirm the importance of oligomerization for the activity of
AML1/ETO in hematopoietic differentiation, proliferation, and
gene expression assays (Hug et al., 2002; Shimada et al.,
2000; Zhang et al., 2001). Disrupting oligomerization partially im-
paired AML1/ETO’s inhibition of granulocyte differentiation,
completely ablated its ability to enhance the clonogenic capac-
ity of primary hematopoietic progenitors, and affected its ability
to influence the expression of endogenous genes in primary
bone marrow stem and progenitor cells.
We also assessed the outcome of disrupting oligomerization
on previously described protein-protein interactions. Eliminating
oligomerization impaired AML1/ETO’s ability to interact, pre-
sumably through tetramerization, with ETO and its homologs
MTG16 and MTGR1, as shown previously with an NHR2 dele-
tion (Kitabayashi et al., 1998). MTG16 is found in complexes in
hematopoietic cells containing other transcription factors such
as SCL, E12/E47, E2.2, Lbd-1, SSDP2, GATA-1, Gfi-1, and
LMO2 (Schuh et al., 2005). If AML1/ETO’s activity in leukemia
is exerted, in part, through complexes containing MTG16, dis-
rupting its ability to form mixed tetramers with MTG16 couldCANCER CELL APRIL 2006potentially interfere with its activity, a hypothesis previously
advanced by others (Amann et al., 2001).
Oligomerization was not required for HDAC1, HDAC2,
HDAC3, N-CoR, SMRT, PKA RIIa, PLZF, mSin3A, or HEB to
coimmunoprecipitate AML1/ETO from cell extracts. Hiebert
and colleagues reported that an NHR2 deletion reduced, but
did not eliminate AML1/ETO (or ETO) binding to mSin3A,
N-CoR, or the HDACs (Amann et al., 2001; Lutterbach et al.,
1998a, 1998b). With a more precise oligomerization mutant,
we did not see a reduction in AML1/ETO binding to these pro-
teins, except formSin3A andN-CoR in the context of a truncated
AML1/ETO protein. This is not to say that interaction with core-
pressors is not important for AML1/ETO’s activity, only that olig-
omerization does not appear to be contributing to AML1/ETO’s
activity by increasing its affinity for these proteins. Oligomeriza-
tion could, however, increase the number of corepressors re-
cruited to the DNA without altering affinity. A tetramer of
AML1/ETO (or a mixed tetramer consisting of AML1/ETO and
other ETO homologs) would have the potential to recruit 4-fold
more repressor molecules to the DNA than monomeric AML1/
ETO, thereby increasing the local concentration of corepressors
on target genes. Another possible mechanism by which oligo-
merization might contribute to AML1/ETO’s activity is by aug-
menting DNA binding, particularly to enhancers and promoters
that contain multiple Runx binding sites, allowing it to effectively
compete with the normal core binding factors for occupancy. A
model for this is the enhanced occupancy of Hox a9 by dimer-
ized forms of MLL (Martin et al., 2003). Establishing cell lines
expressing equivalent amounts of AML1/ETO and m7 will be
necessary to test these various models by chromatin immuno-
precipitation assays.
Disruption of oligomerization in AML1-ETO resulted in clear
changes in the expression of a number of endogenous genes
that have been implicated in the development of leukemia or
myeloproliferative disorders. Some genes were positively and
others negatively regulated by AML1/ETO, as has been ob-
served by others (Shimada et al., 2000, 2002). Some genes
may be direct and others indirect AML1/ETO targets, which
could account for these seemingly opposite activities. The
most intriguing differentially regulated target is the Sfpi1 gene
that encodes PU.1, a transcription factor critical for normal my-
eloid development (McKercher et al., 1996; Scott et al., 1994).
Reductions in PU.1 dosagewere recently shown to cause an ac-
cumulation of c-kit+ hematopoietic precursors in bone marrow,
and predisposedmice to acutemyeloid leukemia and T cell lym-
phoma (Rosenbauer et al., 2004, 2006). AML1/ETO is also
thought to inhibit the transcriptional activity of the PU.1 protein,
and expression of PU.1 in t(8;21) containing Kasumi-1 cells pro-
moted their differentiation (Vangala et al., 2003). AML1/ETO’s
ability to reduce both PU.1 dosage and function could be critical
for establishing the preleukemic state.
Since disrupting tetramer formation ameliorates some of
AML1/ETO’s deleterious in vivo effects, an obvious question is
whether the tetramer interface is a good target for small mole-
cules or peptides that inhibit oligomerization. We predict that
the extremely stable nature of the tetramer, reflected in both
its thermal stability and the extensive mutagenesis necessary
to disrupt its formation, would make developing small molecule
inhibitors of this interaction quite challenging. A more promising
approach might be to disrupt the interaction between AML1/
ETO and the coregulatory molecules important for its activity.257
A R T I C L EIdentifying which of these molecules is critical for oligomeric
AML1/ETO’s oncogenic activity is an important area of investi-
gation.
Experimental procedures
Cloning, expression, and protein purification
Cloning, expression, and protein purification were carried out according to
standard procedures (details provided in Supplemental Data). FLAG-tagged
mammalian expression constructs for HDAC1–HDAC3, N-CoR, and SMRT,
and HA-tagged ETO, MTG16, and MTRG1, were generous gifts from Scott
Hiebert. N-terminal FLAG tagswere added to PKARIIa, HEB, and PLZF using
PCR, and the resulting constructs were cloned into pcDNA3.1(+).
Crystallization
The Se-Met labeled NHR2 domain (AML1/ETO residues 480–551) was dia-
lyzed into 25mMTris (pH 7.5), 15mMNaCl, and 1mMDTT and concentrated
to 10 mg/ml. The protein was mixed 1:1 with well solution (100 mMNaCit [pH
5.6], 100 mM MgCl2, 40% MPD [2-methyl-2,4-pentanediol]) and crystallized
by sitting drop vapor diffusion. Crystals reached their full size in 3–4 days.
Crystals were removed from the mother liquor and frozen in liquid nitrogen
prior to data collection.
Data collection and structure determination
Data were collected from a Se-Met substituted crystal at the beamline X9B at
the National Synchrotron Light Source, Brookhaven National Laboratory.
Three data sets were collected (0.97915 A˚ [peak], 0.97946 A˚ [inflection],
and 0.96422 A˚ [remote]), reduced, and scaled with HKL2000 (Otwinowski
and Minor, 1997). Details of data collection are summarized in Table 1.
The structure was solved with the MAD method. A Se-Met substructure
was found from peak data with SHELXD (Schneider and Sheldrick, 2002).
An initial map was obtained from a single wavelength with SHARP. Due to
low solvent content, a better map was obtained with the use of three wave-
lengths with SHARP (de La Fortelle and Bricogne, 1997) and subsequently
SOLVE/RESOLVE (Terwilliger, 2002). We extended the initial model built by
RESOLVE by manual building with O (Jones et al., 1991). We followed the re-
finement with CNS (Brunger et al., 1998) using the simulated annealing pro-
tocol (Brunger et al., 1990) with manual rebuilding taking into account the 2-
fold noncrystallographic symmetry (NCS). We used a subset of reflections
(5%) for Rfree calculations (Brunger, 1992). Final steps of the refinement
were carried out with REFMAC (Murshudov et al., 1997) without NCS re-
straints. The refinement statistics are summarized in Table 1. Data collected
at 0.97915 A˚ (peak) were used during refinement. The PROCHECK and
MOLPROBITY programs were used for structure validation. The final model
contains two protein chains and 59 water molecules.
Sedimentation velocity measurements
Samples were equilibrated by dialysis into a buffer containing 50mMTris (pH
7.5), 150 mM NaCl, and either 1 mM DTT (NHR2 and m4) or 0.5 mM TCEP
(m7) (pH 7.5). Extinction coefficients, molecular masses, and partial specific
volumes were determined using the SEDNTERP program (Laue et al., 1992).
Sedimentation velocity analytical ultracentrifugation was performed with
a Beckman Coulter XL-I instrument in aluminum-filled double sector cells
at 20ºC and 50,000 RPM using a scan interval ofw260 s. The sedimentation
velocity concentration profiles were fit to finite element solutions of the Lamm
equation using a model of a continuous distribution of discrete, noninteract-
ing species with the program SEDFIT (Schuck, 2000). The molecular mass
and sedimentation coefficient of the predominant species were determined
using a hybrid discrete-continuous model where the major peak was fit as
a single discrete species and the material at higher and lower S was
accounted for by two continuous distributions. Data obtained at multiple
concentrations were globally fit using SEPHAT (Schuck, 2003). Hydrody-
namic bead modeling was performed using the crystallographic coordinates
for the NHR2 domain using the HYDROPRO package (Garcia De La Torre
et al., 2000) with the default effective atomic radii of 3.2 A˚.
Western blots
Western blots were performed using standard protocols (details provided in
Supplemental Data).258Coimmunoprecipitations
Coimmunoprecipitations were performed using standard protocols (details
provided in Supplemental Data).
Retroviral transduction
Phoenix cells were plated in 10 cm dishes in DMEM supplemented with 10%
fetal calf serum and penicillin/streptomycin (FCS, P/S), and transfected after
12–16 hr with 20 mg ofMigR1 plasmids by calcium phosphate in the presence
of chloroquine, and viral supernatants were harvested at 48 hr. Cells were
subjected to 2 hr of spinoculation at 2350 RPM, 25ºC in the presence of poly-
brene, and then cultured for 48 hr with viral supernatant. We determined
transduction efficiencies by assessing the percentage of GFP-positive NIH
3T3 cells with a FACScan flow cytometer (BD Bioscience). Expression of
AML1/ETO proteins was assessed by Western blots of nuclear extracts pre-
pared from transduced NIH 3T3 cells.
Granulocyte differentiation
Bonemarrow (BM) was harvested frommale C57BL/63 129Sv (F1) mice and
cultured for 2 days in DMEM plus FCS P/S, 10 ng/ml IL-3, 20 ng/ml IL-6, 100
ng/ml SCF (R&D Systems). Cells expressing lineage markers were depleted
using a cocktail of antibodies conjugated to magnetic beads (Miltenyi). Line-
age-negative (Lin2) cells were infected with retroviruses expressing GFP
alone, or GFP in combination with AML1/ETO proteins, and cultured for 7
days in DMEM FCS P/S, 10 ng/ml IL-3, 20 ng/ml IL-6, 100 ng/ml SCF, 60
ng/ml G-CSF (R&D Systems). Cells were harvested and stained for surface
expression of Mac1 and Gr-1 (Ly-6C) with antibodies conjugated to PE or
APC, respectively (BD Bioscience) using a FACSCalibur flow cytometer
(BD Bioscience), and the data were analyzed using FloJo software.
Serial replating
Immediately following retroviral transduction, 103 cells were plated in M3434
complete methylcellulose media (Stem Cell Technologies) and cultured for 7
days. After colonies were enumerated, the cultures were diluted and resus-
pended, and 104 cells were replated in M3434 media for an additional 7
days, at which point the process was iteratively repeated as indicated. Cyto-
spins of cells resulting from replatings were generated using a Shandon cy-
tospin and stained with Wright Giemsa.
Real-time PCR
Lin2 BM cells were isolated and transduced with MigR1 expressing GFP,
AML1/ETO, or m7 as described above. After 48 hr of culture in IL-3, IL-6,
and SCF, cells were isolated using a FACSAria Cell Sorting System (BD Bio-
science) based onGFP expression and propidium iodide exclusion. Indepen-
dent FACS analysis of GFP-positive cells stained with a panel of anti-lineage
marker antibodies (Miltenyi, Earhardt, CA) revealed a consistent 95%–98%
lineage negativity in all samples (data not shown). Total RNA was extracted
from sorted cells with RNeasy spin columns and was DnaseI treated (Qiagen
Inc, Valencia, CA). RNA integrity was verified by agarose gel electrophoresis
and quantifiedwith Nano-Drop1000 (Nano-Drop,Wilmington, DE). Total RNA
was subjected to two rounds of T7-based linear amplification using the
RiboAmp RNA Amplification kit (Arcturus Inc, Mountain View, CA). Amplified
RNA (aRNA) from each sample was used to generate three independent
preparations of double-stranded cDNA (dscDNA) for quantitative analysis
of gene expression. An aliquot of this material was subjected to a third round
of amplification in the presence of biotinylated dUTP using the Bioarray High
Yield RNA Transcript Labeling Kit (ENZO, Farmingdale, NY). Biotinylated
RNA was used to interrogate pathway-specific oligonucleotide arrays (He-
matopoietic StemCell andHematopoiesis, andCell Cycle; SuperArray, Fred-
erick, MD) as a primary screen to identify differentially expressed genes.
Real-time quantitative PCR of candidate AML1/ETO target genes was then
performed in triplicate for each sample using SYBR-Green (Applied Biosys-
tems, Foster City, CA) on Applied Biosystems’s 7500 Real-Time PCR Sys-
tem. Linear regression analysis of unknown samples was performed using
the relative standard curve method.
Supplemental data
The Supplemental Data include Supplemental experimental procedures,
one supplemental figure, and one supplemental table and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/4/
249/DC1/.CANCER CELL APRIL 2006
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